DOI: 10.4244/EIJ-D-21-00812L

Letter: Reintervention for a failed surgical aortic bioprosthesis. Percutaneous or surgical treatment: should we look at the short- or long-term perspective?

Thomas Cuisset1,2,3, PhD; Nicolas Jaussaud4, MD; Pierre Morera4, MD; Frederic Collart4, PhD; Pierre Deharo1,2,3, PhD

We read with interest the work of Majmundar et al, published recently by EuroIntervention1. Interestingly, we recently published a large, matched comparison of valve-in-valve transcatheter aortic valve implantation (ViV TAVI) versus redo surgical aortic valve replacement (SAVR)2. We have to congratulate Majmundar and colleagues for providing with their updated work, the largest propensity analysis on this subset of patients. Indeed, the number of patients presenting with a failed aortic bioprosthesis is increasing along with life expectancy. Therefore, those patients represent a new challenge for the physician. Recent European guidelines recommend redo surgery as first-line treatment in case of a failed aortic bioprosthesis due to the paucity of long-term data on ViV TAVI3. However, it now seems to be demonstrated that ViV TAVI is associated with better short-term outcomes than redo SAVR. In the vast majority of cases, ViV TAVI represents a controlled intervention with a low rate of complications, which translates into lower early morbidity and mortality than a second surgery in an elderly patient. Therefore, from a short-term perspective, ViV TAVI is a safe and less invasive treatment when dealing with a degenerated surgical aortic bioprosthesis.

However, long-term outcomes after ViV TAVI remain a matter of debate. Data from our analysis showed, for a mean follow-up of 790 days, higher rates of rehospitalisation for heart failure after ViV TAVI compared to redo SAVR2. Majmundar et al report the same conclusions, with increased risk of hospital readmission as early as 30 days and 6 months after the reintervention. More importantly, their work emphasises that different factors may lead to readmission in ViV TAVI and redo SAVR. Redo SAVR has a particular risk of worse outcomes in case of chronic lung disease and chronic kidney disease. On the other hand, ViV TAVI may be less beneficial in patients with heart failure and atrial fibrillation. Majmundar et al highlight the high rates of readmission for cardiac or non-cardiac causes after reintervention for a failed aortic bioprosthesis. Those conclusions emphasise the need for improvement in this subtype of patients.

Pooled together, these data provide meaningful information considering the growing population with a failed surgical aortic bioprosthesis which will require reintervention. Overall, ViV TAVI has become a valid alternative to redo SAVR and offers better short-term outcomes. However, long-term follow-up mitigates this initial superiority of ViV TAVI over redo SAVR. Although rehospitalisation for heart failure could be increased after ViV TAVI, several factors (such as lung and kidney disease, heart failure, atrial fibrillation) could play a significant role in the decision-making process regarding the type of reintervention (i.e., ViV TAVI vs redo SAVR). Therefore, randomised data and longer follow-up are required to better define which patient will benefit from percutaneous or surgical aortic replacement when facing a degenerated aortic bioprosthesis.

Conflict of interest statement

T. Cuisset reports consulting or speaker activities for Edwards, Boston Scientific and Medtronic. The other authors have no conflicts of interest to declare.

Supplementary data

To read the full content of this article, please download the PDF.

Volume 17 Number 17
Apr 1, 2022
Volume 17 Number 17
View full issue


Key metrics

Suggested by Cory

10.4244/EIJ-E-21-00006 Feb 18, 2022
Valve-in-valve TAVI: the new standard therapy for failing bioprosthetic valves?
Baldus S and Mauri V
free

State-of-the-Art Review

10.4244/EIJ-D-21-00157 Oct 20, 2021
Transcatheter aortic valve implantation in degenerated surgical aortic valves
Tarantini G et al
free

10.4244/EIJV9SSA15 Sep 15, 2013
Failing surgical bioprosthesis in aortic and mitral position
Mylotte D et al
free

10.4244/EIJV14I18A313 Apr 5, 2019
Transcatheter aortic valve implantation in patients at low surgical risk
Søndergaard L et al
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved